ticagrelor / Generic mfg. - LARVOL DELTA

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: University of Florida | Trial completion date: Apr 2026 ➔ Apr 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Rationale and design of Ticagrelor with Aspirin Dual Antiplatelet Therapy Combined with Intravenous Thrombolysis in Patients with Ischemic Stroke (TAPIS): a multicentre, randomised, double-blind, parallel group, placebo-controlled trial. (PubMed, Stroke Vasc Neurol) - P3 | "This trial will evaluate whether early dual antiplatelet therapy with ticagrelor plus aspirin could improve functional outcomes of IVT-treated AIS patients."

Journal • Cardiovascular • Ischemic stroke

Pharmacokinetic Modeling of Ticagrelor and Ticagrelor Active Metabolite Removal by the DrugSorb-ATR Device in a Randomized Controlled Study of Patients Undergoing Cardiac Surgery. (PubMed, J Cardiovasc Pharmacol) - "The model demonstrated that DrugSorb-ATR significantly reduced unbound ticagrelor and TAM concentrations. Linear and logistic regression analyses of summed ticagrelor and TAM concentrations showed that the DrugSorb-ATR device reduced the probability of clinically relevant bleeding in STAR-T because of the reduction in unbound ticagrelor and TAM."

Clinical • Journal • PK/PD data • Cardiovascular

Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y12 Inhibitor Therapy. (PubMed, JACC Adv) - "Higher SDI was associated with an increased risk of MAE with clopidogrel and bleeding with alternative therapy following PCI. Whether addressing socioeconomic disparities improves P2Y12 inhibitor-related outcomes remains to be determined."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Thrombosis

Ticagrelor and prevention of infective endocarditis in patients at risk: a population-based study (ESCMID Global 2026) - No abstract available

Clinical • Cardiovascular

Safety profile of ticagrelor: an analysis based on literature and database review. (PubMed, BMC Cardiovasc Disord) - No abstract available

Journal

Comparative efficacy of pharmacological agents on abdominal aortic aneurysm growth rate: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Roxithromycin also demonstrated advantages over amlodipine and doxycycline in indirect comparisons. Propranolol, perindopril, metformin, azithromycin, and ticagrelor showed no significant benefits...Roxithromycin, statins, and metformin show promise for potentially limiting AAA expansion. However, findings are constrained by methodological limitations (study design, sample size), necessitating future validation via high-quality RCTs."

Journal • Retrospective data • Review • Cardiovascular

The Efficacy of Tapentadol versus Sufentanil in Preventing Postoperative Nausea and Vomiting after Gynecological Laparoscopic Surgery:A Randomized, Double-Blind, Controlled Trial (ChiCTR) - P4 | N=276 | Not yet recruiting | Sponsor: International Peace Maternity and Child Health Hospital; International Peace Maternity and Child Health Hospital

New P4 trial

Low-Dose Versus Standard-Dose Ticagrelor for Secondary Stroke Prevention in Minor Stroke or High-Risk TIA Patients with CYP2C19 Loss-of-Function Alleles (LIGHT): A Randomized Non-Inferiority Trial (ChiCTR) - P=N/A | N=1624 | Not yet recruiting | Sponsor: Yichang Central People's Hospital; Yichang Central People's Hospital

New trial • Cardiovascular • Ischemic stroke • CYP2C19

The Application of Tigilide for Postoperative Analgesia in Patients Undergoing Hysteroscopic Surgery: A Prospective, Randomized, Double-Blind, Controlled Study (ChiCTR) - P=N/A | N=94 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Anhui University of Science and Technology; The First Affiliated Hospital of Anhui University of Science and Technolo

New trial

Real-world Study on Clinical Characteristics and Risk Factors of Ticagrelor-related Dyspnea (ChiCTR) - P=N/A | N=5000 | Not yet recruiting | Sponsor: Chinese Academy of Medical Sciences Peking Union Medical College TEDA International Cardiovascular Hospital; Chinese Academy of Medical Sciences Pekin

New trial • Cardiovascular • Coronary Artery Disease • Heart Failure • Pulmonary Disease

Antiplatelet Therapy Combinations and Outcomes after Spontaneous Intracerebral Hemorrhage in the AHA Get With The Guidelines Registry (ISC 2026) - "The exposure was the type of APT defined as either monothrerapy (aspirin, clopidogrel, prasugrel, ticagrelor used alone), dual APT combinations involving these 4 medications, or no APT. In a large, diverse US cohort of ICH patients, increasing potency of antiplatelet therapy at the time of ICH was associated with higher mortality and a trend toward poor discharge disposition. Better knowledge of these relationships will be crucial in the management of antiplatelet associated ICH."

Cardiovascular • Cerebral Hemorrhage • Hematological Disorders

Pipeline Flex-Shield™ Embolization Device 60 Day Dual Antiplatelet Therapy (DAPT) Followed by 305 Day Aspirin Early Feasibility Study (EFS) 1 Year Study (ISC 2026) - "All received 60 days of DAPT with aspirin (325 mg) and clopidogrel (75 mg); clopidogrel non-responders (P2Y12 > 200) received ticagrelor (90 mg BID) instead. Preliminary results suggest early promise for discontinuing DAPT at 60 days following PED Shield placement. The study is now accelerating enrollment to expand the cohort and strengthen evidence supporting early DAPT cessation."

Anesthesia • Cardiovascular • Hematological Disorders • Ophthalmology • Thrombosis • Vascular Neurology

Impact of Lipoprotein(a) on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack: A Post Hoc Analysis of the CHANCE-2 Trial (ISC 2026) - "This post hoc analysis of the CHANCE-2 trial suggests that Lp(a) may serve as a potential biomarker for identifying CYP2C19 loss-of-function carriers with minor stroke or TIA who benefit more from ticagrelor–aspirin therapy compared to clopidogrel–aspirin therapy."

Clinical • Retrospective data • Atherosclerosis • Cardiovascular • CYP2C19

Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis. (PubMed, Open Heart) - "Off-label low-dose antiplatelet therapy reduces the risks of MI and minimal bleeding. It surpassed standard-dose clopidogrel and offered lower bleeding risks than prasugrel or ticagrelor, thus representing an effective secondary prevention strategy for Asian CHD."

Clinical • Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Infarction

Impact of intraprocedural antiplatelet therapy on stent patency and safety after emergent intracranial stenting in acute ischaemic stroke: insights from the RESISTANT registry. (PubMed, Eur Stroke J) - "In the setting of EIS, intravenous APT agents (Cangrelor or GPi) were associated with improved stent patency and higher rates of successful reperfusion, without a significant increase in symptomatic haemorrhage."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Ischemic stroke

Comparative Efficacy of Ticagrelor and Clopidogrel in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Imaging-Based Pilot Study. (PubMed, Acta Cardiol Sin) - "Ticagrelor and clopidogrel showed similar effects on CMR-based myocardial injury and long-term outcomes in STEMI patients undergoing PCI. These pilot findings are hypothesis-generating and support the feasibility and inform sample-size planning for future multicenter trials."

Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

ACUTE CORONARY SYNDROME WITH STENT THROMBOSIS: HEPARIN-INDUCED THROMBOCYTOPENIA WITH FALSE-NEGATIVE SEROTONIN RELEASE ASSAY IN A PATIENT ON TICAGRELOR (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

TRIPLE ANTITHROMBOTIC THERAPY WITH TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PCI FOR ACUTE MYOCARDIAL INFARCTION (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Atrial Fibrillation • Cardiovascular • Myocardial Infarction

TICAGRELOR VS PRASUGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE MYOCARDIAL INFARCTION: A PROPENSITY-SCORE MATCHED ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular • Myocardial Infarction

Discovery and Evaluation of Novel Calenduloside E Derivatives Targeting HSP90β in Ox-LDL-Induced HUVECs Injury. (PubMed, Pharmaceuticals (Basel)) - "In this study, the CE scaffold was hybridized with a ticagrelor-derived fragment to enhance anti-atherosclerotic activity...Its effective concentration is significantly improved compared with that of the parent CE, which provides a possibility for reducing clinical dosage and toxic side effects in subsequent studies. Furthermore, C5 may exert its effects by targeting another potential target, P2Y12, offering references for the rational design of novel anti-atherosclerotic drugs."

Journal • Atherosclerosis • Cardiovascular • CDC37 • HSP90AA1

EARLY CORONARY ARTERY BYPASS GRAFTING IN STEMI PATIENTS PRE-LOADED WITH TICAGRELOR OR CLOPIDOGREL: CLINICAL AND SAFETY OUTCOMES (ACC 2026) - "Abstract is embargoed at this time."

Clinical

WHEN THE AIR GETS THIN: TICAGRELOR-LINKED DYSPNEA IN MOUNTAIN POPULATIONS (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Pulmonary Disease

TICAGRELOR PLUS ASPIRIN VS ASPIRIN MONOTHERAPY IN PATIENTS UNDERGOING CABG: A SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Monotherapy • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure • Reperfusion Injury

COMPARATIVE EFFICACY AND SAFETY OF TICAGRELOR AND CLOPIDOGREL IN COMPLEX PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data